Seagen is a global biotechnology company dedicated to developing revolutionary therapies with real impact.
Improving the lives of people with cancer through innovative targeted therapies
To discover, develop, and commercialize transformative cancer medicines to make a meaningful difference in people’s lives
Revolutionizing therapy for people living with cancer
Honesty, respect, and trust guide us
Premier science empowers our passion
Shared dedication drives successful collaborations
Entrepreneurial spirit advances breakthrough therapies
Commitment and opportunity inspire purposeful contribution
Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.
As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies to deliver cell-killing agents directly to cancer cells. This technology is the foundation of two of our approved medicines—ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv).
Today, our research efforts are focused on advancing a pipeline of novel targeted therapies, including TUKYSA® (tucatinib), recently approved for certain metastatic HER2+ breast cancers. We’re also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.